Male Sexual Dysfunction Medical Services in China

Male Sexual Dysfunction (MSD) refers to a persistent or recurrent inability to attain and/or maintain an adequate penile erection (erectile dysfunction), ejaculate prematurely (premature ejaculation), experience delayed or absent ejaculation, or sustain sexual desire (hypoactive sexual desire disorder). It encompasses biopsychosocial disturbances affecting sexual response, satisfaction, and interpersonal intimacy. Pathogenesis is multifactorial: organic causes include vascular insufficiency (e.g., endothelial dysfunction from atherosclerosis), neurologic impairment (e.g., diabetic neuropathy, spinal cord injury), endocrine disorders (hypogonadism, hyperprolactinemia, thyroid dysfunction), pharmacologic effects (antidepressants, antihypertensives), and pelvic surgery or trauma. Psychogenic contributors—such as performance anxiety, depression, relationship conflict, and early negative sexual experiences—often coexist with or amplify organic factors. Epidemiologic studies indicate that approximately 30–50% of men aged 40–70 experience some degree of erectile dysfunction, with prevalence rising steadily with age; premature ejaculation affects an estimated 20–30% of adult men globally. Risk factors span modifiable and non-modifiable domains: cardiovascular disease, metabolic syndrome, obesity, smoking, excessive alcohol use, sedentary lifestyle, untreated depression or anxiety, chronic stress, sleep apnea, and aging. Importantly, MSD is strongly associated with underlying systemic pathology—serving as an early sentinel for cardiovascular disease—and warrants comprehensive medical evaluation beyond symptom management. The quality-of-life impact is profound: men report diminished self-esteem, increased psychological distress, reduced work productivity, strained intimate relationships, and higher rates of marital dissatisfaction or separation. Partners often experience decreased sexual satisfaction, emotional distance, and secondary anxiety—highlighting the dyadic nature of sexual health. Untreated MSD correlates with elevated risks of depression, social withdrawal, and reduced overall life satisfaction. Early diagnosis and integrated care—spanning urology, endocrinology, psychology, and reproductive medicine—are essential to address both physiological mechanisms and psychosocial consequences. In the Department of Reproductive Medicine, MSD evaluation emphasizes fertility implications (e.g., ejaculatory failure impairing conception), hormonal profiling (testosterone, prolactin, LH, FSH, SHBG), vascular assessment, and personalized behavioral interventions alongside pharmacotherapy.

Male sexual dysfunction (MSD) encompasses a spectrum of conditions—including erectile dysfunction (ED), premature ejaculation (PE), delayed ejaculation, anejaculation, and hypoactive sexual desire disorder—that impair sexual performance, satisfaction, or reproductive function. In the Department of Reproductive Medicine, evaluation begins with a comprehensive biopsychosocial assessment: detailed sexual history, physical examination (including genital inspection, neurological screening, and cardiovascular risk profiling), hormonal profiling (total and free testosterone, prolactin, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone), and validated questionnaires (e.g., International Index of Erectile Function-5, Premature Ejaculation Profile). Additional diagnostics may include nocturnal penile tumescence testing, intracavernosal injection pharmacotesting, duplex Doppler ultrasonography, and semen analysis when fertility concerns coexist.

Conservative treatment forms the cornerstone of initial management. Lifestyle optimization is evidence-based and first-line: sustained weight loss (>5% body weight) in overweight/obese men improves endothelial function and testosterone levels; aerobic exercise ≥150 minutes/week enhances nitric oxide bioavailability and reduces systemic inflammation; smoking cessation and alcohol moderation directly improve cavernosal smooth muscle relaxation and microvascular integrity. Psychological interventions—particularly cognitive-behavioral therapy (CBT) and mindfulness-based sex therapy—are indicated for performance anxiety, relationship discord, or depression-related sexual inhibition. Pelvic floor muscle training (PFMT), guided by urological physiotherapists, demonstrates efficacy in both PE (via improved ejaculatory control) and mild ED (by enhancing bulbocavernosus reflex and veno-occlusive competence). Nutritional counseling emphasizes Mediterranean-pattern diets rich in nitrates (leafy greens), antioxidants (berries, nuts), and omega-3 fatty acids (fatty fish), while discouraging ultra-processed foods and excessive saturated fats.

Pharmacotherapy is stratified by etiology and severity. For organic ED, phosphodiesterase type 5 inhibitors (PDE5is)—sildenafil, tadalafil, vardenafil, and avanafil—are first-line. Tadalafil’s 36-hour half-life supports flexible dosing (on-demand or daily low-dose 2.5–5 mg), particularly beneficial in men with concomitant lower urinary tract symptoms. Intracavernosal alprostadil injections remain highly effective for neurogenic or post-prostatectomy ED unresponsive to oral agents, with >80% success rates in rigorous trials. Topical alprostadil cream (Vitaros®) offers a non-invasive alternative, though absorption variability limits consistency. For PE, on-demand dapoxetine (a short-acting selective serotonin reuptake inhibitor) is FDA- and EMA-approved and significantly increases intravaginal ejaculatory latency time (IELT); daily SSRIs (e.g., paroxetine, sertraline) are reserved for lifelong PE with comorbid depression. Off-label topical anesthetics (e.g., lidocaine-prilocaine cream) require careful application to avoid partner numbness and must be washed prior to intercourse. Hormonal therapy is strictly indicated only in confirmed hypogonadism (total testosterone <8 nmol/L with symptomatic deficiency); transdermal gels or intramuscular testosterone undecanoate restore libido and energy but require monitoring of hematocrit, prostate-specific antigen (PSA), and sleep apnea symptoms.

Surgical intervention is considered only after failure of conservative and medical therapies. Penile prosthesis implantation—either malleable (semi-rigid) or inflatable (two- or three-piece)—offers >95% patient and partner satisfaction rates and durable restoration of rigidity. Modern inflatable devices feature antibiotic-coated cylinders and refined hydraulic mechanisms minimizing mechanical failure (<5% at 5 years). Vascular surgery (e.g., arterial bypass for young traumatic arterial insufficiency) is exceedingly rare and limited to highly selected cases (<1% of ED referrals) due to poor long-term patency. Microsurgical sperm retrieval (e.g., micro-TESE) is not a treatment for MSD per se but is integrated when MSD coexists with obstructive or non-obstructive azoospermia requiring assisted reproductive technology.

Treatment in China offers distinct advantages within the Reproductive Medicine framework. First, integrated multidisciplinary teams—comprising reproductive endocrinologists, andrologists, clinical psychologists, pelvic floor therapists, and traditional Chinese medicine (TCM) practitioners—enable seamless coordination. While Western pharmacotherapy is standard, evidence-informed TCM adjuncts (e.g., Bushen Yiqi decoction for kidney-yang deficiency patterns) are offered where robust RCT data support synergistic effects on endothelial function and oxidative stress. Second, China’s national health infrastructure ensures rapid access to advanced diagnostics: high-resolution penile Doppler ultrasound with quantitative flow metrics, automated semen morphology analysis (strict criteria), and genetic testing (e.g., Y-chromosome microdeletion screening) are widely available in tier-3 hospitals. Third, cost-effectiveness is notable: generic PDE5is and domestically manufactured prostheses reduce out-of-pocket expenses by 40–60% versus Western markets, without compromising quality standards (CFDA/NMPA certification). Fourth, digital health integration—including AI-assisted symptom tracking apps linked to hospital EMRs and tele-rehabilitation for PFMT—enhances adherence and longitudinal monitoring.

Post-treatment recovery requires structured, individualized guidance. Patients initiating PDE5is should be counseled on optimal timing (e.g., sildenafil 60 minutes pre-intercourse, avoiding high-fat meals), realistic expectations (success rates ~70% in mild-moderate ED), and safety parameters (contraindication with nitrates, caution in uncontrolled hypertension). After prosthesis surgery, strict wound care, abstinence for 6 weeks, and graded device activation under clinician supervision prevent complications. All patients receive written sexual rehabilitation protocols: graded exposure exercises for anxiety reduction, sensate focus techniques to decouple performance pressure from intimacy, and scheduled ‘non-goal-oriented’ touch sessions. Follow-up intervals are protocol-driven: 2 weeks post-initiation of any new therapy, then monthly for 3 months, transitioning to quarterly for stable responders. Long-term surveillance includes annual testosterone and PSA checks for hormonal therapy recipients, and duplex ultrasound at 12 months post-prosthesis to assess corporal integrity. Crucially, partners are actively engaged in counseling—joint sessions address communication barriers, shared goal-setting, and mutual understanding of physiological constraints—recognizing that MSD is a dyadic, not merely individual, health concern. With this comprehensive, patient-centered, and evidence-grounded approach, over 85% of men with MSD achieve clinically meaningful improvement in sexual function and quality of life within 6 months.